Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524702 | 0.98 | SHBG (0.48) | SHBGEPHX1ALDH1A1TP53 | |
| SCHEMBL232044 | 0.93 | — | — | |
| SCHEMBL7089601 | 0.89 | SHBG (0.46) | SHBGEPHX1ALDH1A1TP53 | |
| SCHEMBL910631 | 0.87 | — | — | |
| SCHEMBL9213980 | 0.85 | EPHX1 (0.42) | SHBGEPHX1ALDH1A1TP53KDM4E | |
| SCHEMBL5400953 | 0.85 | SHBG (0.62) | SHBGEPHX1ALDH1A1TP53KDM4E | |
| SCHEMBL20600160 | 0.82 | SHBG (0.48) | SHBGEPHX1ALDH1A1TP53KDM4E | |
| SCHEMBL16703627 | 0.82 | SHBG (0.43) | SHBGEPHX1ALDH1A1TP53KDM4E | |
| SCHEMBL2342491 | 0.82 | SHBG (0.57) | SHBGEPHX1ALDH1A1TP53KDM4E | |
| SCHEMBL9202551 | 0.82 | EPHX1 (0.38) | SHBGEPHX1ALDH1A1TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240188441-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE, AND THE CONDENSED CYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-06-06 | — | — | US | claimed |
| US-20240188441-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE, AND THE CONDENSED CYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-06-06 | — | — | US | disclosed |
| CN-117986280-A | Light-emitting device, electronic apparatus, electronic device, and condensed cyclic compound | 三星显示有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116425780-A | Light-emitting device comprising condensed cyclic compound, electronic equipment and said compound | 三星显示有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230225207-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE SAME, AND THE CONDENSED CYCLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230225190-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| CN-116410232-A | Organometallic compound, light-emitting device including the same, and electronic device | 三星显示有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-9012413-B2 | FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-04-21 | — | — | US | disclosed |
| US-8975248-B2 | Combinations of therapeutic agents for treating cancer | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2112154-B1 | Esters in position 20 of camptothecins | SIGMA TAU IND FARMACEUTI (IT) | 2013-07-24 | — | — | EP | disclosed |
| US-20030148878-A1 | Catalyst system for fluorous biphasic catalysis processes which comprises functionalized polymeric beads, monodisperse SiO2 or SiO2 flakes associated with the catalyst. These functionalized particles are used as a support for catalysts | MERCK PATENT GMBH (DE) | 2003-08-07 | — | — | US | disclosed |
| US-6589939-B2 | Also useful in treating viral infections; antiprotozoa (plasmodium) activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| EP-1307287-A2 | CATALYST ASSOCIATED WITH FUNCTIONALIZED PLASTIC BEADS OR SILICA FOR USE IN FLUOROUS BIPHASIC CATALYSIS | MERCK PATENT GmbH (DE) | 2003-05-07 | — | — | EP | disclosed |
| EP-1044977-B1 | Camptothecin derivatives having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2002-05-02 | — | — | EP | disclosed |
| WO-2002004120-A2 | CATALYST ASSOCIATED WITH FUNCTIONALIZED PLASTIC BEADS OR SILICA FOR USE IN FLUOROUS BIPHASIC CATALYSIS | MERCK PATENT GMBH (DE) | 2002-01-17 | — | — | WO | disclosed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | disclosed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | disclosed |
| EP-1044977-A1 | Camptothecin derivatives having antitumor activity | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
| EP-0454302-A2 | Tuftsin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225207-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE SAME, AND THE CONDENSED CYCLIC COMPOUND | CRY1, CRY2, CCNE2 | SHBG 1908/4885EPHX1 899/4885ALDH1A1 408/4885 |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | SHBG 3408/4885EPHX1 2510/4885ALDH1A1 2202/4885 |
| US-20240188441-A1 | LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND, ELECTRONIC APPARATUS AND ELECTRONIC DEVICE INCLUDING THE LIGHT-EMITTING DEVICE, AND THE CONDENSED CYCLIC COMPOUND | CRY1, ELP1, CCNE2 | SHBG 1814/4885EPHX1 400/4885ALDH1A1 236/4885 |
| US-20230225190-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | LIG1, CRY1, LAGE3 | SHBG 2120/4885EPHX1 852/4885ALDH1A1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.